Share of Clicks for top 10 US Pharma & Biotech Research and Development brands
Here are the Top 10 competitors in the industry by Share of Clicks for the last month.
| Domain | Share of clicks |
|---|---|
| lilly.com | 39.07 |
| merck.com | 5.39 |
| gsk.com | 4.37 |
| ro.co | 3.92 |
| pfizerforall.com | 3.91 |
| regeneron.com | 3.75 |
| evenity.com | 3.11 |
| abbvie.com | 3.02 |
| ubrelvyhcp.com | 2.35 |
| sequencing.com | 1.8 |
| others | 29.31 |
- lilly.com - 39.07%
- merck.com - 5.39%
- gsk.com - 4.37%
- ro.co - 3.92%
- pfizerforall.com - 3.91%
- regeneron.com - 3.75%
- evenity.com - 3.11%
- abbvie.com - 3.02%
- ubrelvyhcp.com - 2.35%
- sequencing.com - 1.8%
- others - 29.31%
Copyright © Adthena. All rights reserved.
In the PPC landscape, Lilly.com dominates with 39.07% click share, overshadowing Merck.com at 5.39%. Others collectively hold 29.31%, highlighting diverse competition.
Share of Spend for the top 10 US Pharma & Biotech Research and Development brands
Curious about your market position? Here you can see the Top 10 competitors in the industry by Share of Spend for the last month.
| Date | lilly.com | evenity.com | pfizerforall.com | ro.co | ubrelvyhcp.com | merck.com | tecvayli.com | scemblix.com | capvaxive.com | ziphealth.co |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026/09/01 | 43.47% | 2.62% | 2.73% | 4.55% | 1.64% | 1.67% | 0.34% | 1.45% | 0.98% | 3.89% |
| 2026/09/02 | 43.39% | 0.49% | 0.89% | 8.51% | 1.98% | 1.99% | 0.29% | 1.97% | 1.14% | 6.16% |
| 2026/09/03 | 45.26% | 0.7% | 0.64% | 8.17% | 2.73% | 1.38% | 0.35% | 1.39% | 1.31% | 5.79% |
| 2026/09/04 | 46.33% | 1.8% | 0.81% | 5.78% | 1.36% | 1.43% | 0.25% | 1.81% | 1.23% | 5.28% |
| 2026/09/05 | 38.59% | 1.84% | 6.66% | 8.62% | 1.68% | 1.89% | 0.52% | 1.72% | 0.72% | 7.08% |
| 2026/09/06 | 41.24% | 3.49% | 6.41% | 5.1% | 2.05% | 2.41% | 1.1% | 1.42% | 0.95% | 4.81% |
| 2026/09/07 | 38.29% | 4.68% | 5.83% | 5.09% | 1.29% | 2.29% | 0.62% | 1.49% | 0.7% | 5.21% |
| 2026/09/08 | 42.72% | 3.02% | 6.33% | 3.64% | 1.81% | 2.38% | 0.48% | 1.74% | 1.03% | 3.25% |
| 2026/09/09 | 39.2% | 3.37% | 6.97% | 4.64% | 1.77% | 2.03% | 0.46% | 1.3% | 1.02% | 1.58% |
| 2026/09/10 | 39.07% | 3.71% | 5.88% | 5.91% | 1.61% | 1.97% | 0.63% | 1.68% | 0.99% | 3.97% |
| 2026/09/11 | 37.46% | 4.34% | 5.56% | 7.86% | 1.53% | 2.06% | 0.85% | 1.02% | 0.97% | 1.63% |
| 2026/09/12 | 39.47% | 6.74% | 6.45% | 4.47% | 1.45% | 2.03% | 0.88% | 1.77% | 1.21% | 0.53% |
| 2026/09/13 | 39.53% | 6.36% | 5.94% | 5.53% | 1.11% | 2.42% | 0.96% | 1% | 0.99% | 0.83% |
| 2026/09/14 | 38.04% | 6.3% | 6.72% | 4.93% | 1.59% | 1.6% | 0.9% | 1.41% | 0.94% | 2.31% |
| 2026/09/15 | 32.15% | 7.98% | 8.22% | 4.55% | 2.99% | 1.87% | 1.3% | 1.37% | 1.18% | 0.02% |
| 2026/09/16 | 30.58% | 8.52% | 8.1% | 3.84% | 2.51% | 2.19% | 1.53% | 1.62% | 1.03% | 0.97% |
| 2026/09/17 | 26.85% | 8.79% | 5.91% | 4.32% | 2.57% | 2.15% | 1.59% | 1.82% | 1.18% | 0.95% |
| 2026/09/18 | 27.35% | 9.05% | 6.98% | 3.78% | 3.05% | 2.51% | 1.62% | 1.69% | 1.1% | 0.94% |
| 2026/09/19 | 39.34% | 7.35% | 6.02% | 3.63% | 2.72% | 2.03% | 1.37% | 1.34% | 1.06% | 1.24% |
| 2026/09/20 | 33.08% | 7.47% | 6.04% | 9.07% | 2.58% | 2.24% | 1.46% | 1.2% | 1.11% | 1.27% |
| 2026/09/21 | 28.18% | 9.24% | 8.15% | 3.05% | 3.24% | 1.88% | 1.61% | 1.46% | 1.34% | 0.29% |
| 2026/09/22 | 29.15% | 8.82% | 7.57% | 8.19% | 2.22% | 1.87% | 1.65% | 2.03% | 1.3% | 0.28% |
| 2026/09/23 | 29.89% | 8.54% | 7.26% | 10.52% | 2.55% | 1.57% | 1.2% | 1.19% | 1.12% | 1.41% |
| 2026/09/24 | 35.55% | 7.93% | 6.22% | 3.33% | 2.74% | 1.59% | 1.29% | 1.34% | 0.94% | 0.82% |
| 2026/09/25 | 29.6% | 7.96% | 6.46% | 8.25% | 2.08% | 1.92% | 1.61% | 1.45% | 1.11% | 0.82% |
| 2026/09/26 | 37.96% | 7.72% | 5.99% | 5.66% | 2.55% | 1.68% | 1.56% | 1.11% | 1.09% | 0% |
| 2026/09/27 | 33.08% | 7.38% | 5.85% | 6.61% | 2% | 1.53% | 1.42% | 1.41% | 0.84% | 2.28% |
| 2026/09/28 | 28.02% | 9.27% | 7.79% | 7.05% | 2.81% | 0.74% | 1.53% | 1.64% | 1.15% | 0.49% |
| 2026/09/29 | 26.22% | 8.76% | 6.83% | 6.34% | 2.88% | 1.79% | 1.71% | 1.57% | 1.22% | 1% |
| 2026/09/30 | 24% | 9.64% | 6.42% | 4.17% | 3.85% | 2.86% | 1.94% | 1.87% | 1.51% | 0.31% |
- lilly.com
- evenity.com
- pfizerforall.com
- ro.co
- ubrelvyhcp.com
- merck.com
- tecvayli.com
- scemblix.com
- capvaxive.com
- ziphealth.co
Copyright © Adthena. All rights reserved.
Lilly.com started strong but declined, ending at 24.00. Evenity.com rose steadily, finishing at 9.64. Pfizerforall.com fluctuated, closing at 6.42. Ro.co peaked mid-month, ending at 4.17.
Competitor Count for US Pharma & Biotech Research and Development
Ever wondered how many competitors you’re up against in your industry? Well look no further, here we can see the number of advertisers bidding over the last month.
| Date | Competitor Count |
|---|---|
| 2026/09/01 | 364 |
| 2026/09/02 | 372 |
| 2026/09/03 | 370 |
| 2026/09/04 | 364 |
| 2026/09/05 | 368 |
| 2026/09/06 | 391 |
| 2026/09/07 | 412 |
| 2026/09/08 | 411 |
| 2026/09/09 | 413 |
| 2026/09/10 | 410 |
| 2026/09/11 | 405 |
| 2026/09/12 | 412 |
| 2026/09/13 | 413 |
| 2026/09/14 | 393 |
| 2026/09/15 | 406 |
| 2026/09/16 | 401 |
| 2026/09/17 | 395 |
| 2026/09/18 | 405 |
| 2026/09/19 | 396 |
| 2026/09/20 | 388 |
| 2026/09/21 | 385 |
| 2026/09/22 | 387 |
| 2026/09/23 | 381 |
| 2026/09/24 | 395 |
| 2026/09/25 | 385 |
| 2026/09/26 | 373 |
| 2026/09/27 | 375 |
| 2026/09/28 | 388 |
| 2026/09/29 | 379 |
| 2026/09/30 | 382 |
Copyright © Adthena. All rights reserved.
September saw a dynamic shift in advertisers, starting at 364 and peaking at 413 mid-month. The month concluded with a slight dip, ending at 382.
